The TheraCyte™ Device Protects against Islet Allograft Rejection in Immunized Hosts

Clinically, many candidates for islet transplantation are already immunized, which increases their risk of graft rejection. Encapsulation of pancreatic islets using the TheraCyte™ device has been shown to protect against allograft rejection in nonimmunized recipients. However, the capacity of the TheraCyte™ device to prevent rejection in immunized recipients has not yet been studied. In this study, the protective capacity of the TheraCyte™ device was evaluated in an allogeneic rat model. Lewis rats were used as islet donors, and nonimmunized (control) and alloimmunized, diabetic Wistar–Furth (WF) rats were used as recipients. Graft survival was shorter in immunized recipients than in nonimmunized recipients (mean survival, 5.3 ± 2.7 and 9.3 ± 1.6 days, respectively, p < 0.01) when nonencapsulated islets were transplanted under the kidney capsule. When islets were transplanted into the TheraCyte™ device, graft function was maintained during the 6-month study period in both immunized and nonimmunized rats. In oral glucose tolerance tests performed at 1 month after transplantation, both groups had similar insulin and blood glucose levels indicating similar metabolic functions. Volume densities and absolute volumes of tissue inside the devices 6 months after transplantation were also comparable between the two groups, indicating that both groups maintained similar amounts of endocrine tissue. A higher number of IFN-γ-producing CD8+ T-cells were detected in immunized WF rats compared to control WF rats transplanted with encapsulated islets. This suggests that donor-specific alloreactivity in recipient rats was sustained throughout the study period. This study suggests that the TheraCyte™ device protects islet allografts also in immunized recipients. Our results further highlight the potential for using macroencapsulation to avoid immunosuppressive therapy in clinical islet transplantation.

[1]  T. Loudovaris,et al.  CD4+ T cell mediated destruction of xenografts within cell-impermeable membranes in the absence of CD8+ T cells and B cells. , 1996, Transplantation.

[2]  D. Harlan,et al.  Current Advances and Travails in Islet Transplantation , 2009, Diabetes.

[3]  A. Wernerson,et al.  Preimplantation of an Immunoprotective Device Can Lower the Curative Dose of Islets to That of Free Islet Transplantation—Studies in a Rodent Model , 2008, Transplantation.

[4]  A. Lew,et al.  Protection of Xenografts by a Combination of Immunoisolation and a Single Dose of Anti-CD4 Antibody , 2001, Cell transplantation.

[5]  S K Young,et al.  Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization. , 1996, Transplantation.

[6]  R. Wilkinson,et al.  High frequencies of circulating IFN‐γ‐secreting CD8 cytotoxic T cells specific for a novel MHC class I‐restricted Mycobacterium tuberculosis epitope in M. tuberculosis‐infected subjects without disease , 2000 .

[7]  A. M. Shapiro,et al.  High Risk of Sensitization After Failed Islet Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  R. C. Johnson,et al.  Neovascularization of synthetic membranes directed by membrane microarchitecture. , 1995, Journal of biomedical materials research.

[9]  J. Kapp,et al.  Proliferative and Cytokine Responses in CTLA4-Ig-Treated Diabetic NOD Mice Transplanted with Microencapsulated Neonatal Porcine ICCs , 2002, Cell transplantation.

[10]  Michael V Sefton,et al.  In Vivo Recognition by the Host Adaptive Immune System of Microencapsulated Xenogeneic Cells , 2004, Transplantation.

[11]  A. Sharma,et al.  Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes , 2006, Diabetologia.

[12]  T. Loudovaris,et al.  Destruction of xenografts but not allografts within cell impermeable membranes. , 1992, Transplantation proceedings.

[13]  J. Banchereau,et al.  DETECTION OF SINGLE CELLS SECRETING IFN‐GAMMA, IL‐6, AND IL‐10 IN IRREVERSIBLY REJECTED HUMAN KIDNEY ALLOGRAFTS, AND THEIR MODULATION BY IL‐2 AND IL‐4 , 1993, Transplantation.

[14]  A. Shapiro,et al.  Five-year follow-up after clinical islet transplantation. , 2005, Diabetes.

[15]  A. Shapiro,et al.  Liraglutide, a long‐acting human glucagon‐like peptide 1 analogue, improves human islet survival in culture , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  Weibel Er,et al.  Morphometry of the human lung: the state of the art after two decades. , 1979 .

[17]  A. Remuzzi,et al.  Effect of islet transplantation on metabolic glucose control in rats with diabetes. , 2009, Diabetes technology & therapeutics.

[18]  A. Wernerson,et al.  Exendin-4 Increases the Expression of Hypoxia-Inducible Factor-1α in Rat Islets and Preserves the Endocrine Cell Volume of Both Free and Macroencapsulated Islet Grafts , 2012, Cell transplantation.

[19]  Å. Lernmark,et al.  Treatment of diabetic rats with encapsulated islets , 2008, Journal of cellular and molecular medicine.

[20]  J. Connolly,et al.  Evidence for Induced Expression of HLA Class II on Human Islets: Possible Mechanism for HLA Sensitization in Transplant Recipients , 2009, Transplantation.

[21]  A. Wernerson,et al.  Macroencapsulation Protects Against Sensitization after Allogeneic Islet Transplantation in Rats , 2006, Transplantation.

[22]  T. Berney,et al.  Evidence for Humoral Rejection of a Pancreatic Islet Graft and Rescue with Rituximab and IV Immunoglobulin Therapy , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  A. Wernerson,et al.  Improved Survival of Macroencapsulated Islets of Langerhans by Preimplantation of the Immunoisolating Device: A Morphometric Study , 2003, Cell transplantation.

[24]  J. Nordenström,et al.  Survival of Macroencapsulated Allogeneic Parathyroid Tissue One Year after Transplantation in Nonimmunosuppressed Humans , 2001, Cell transplantation.

[25]  J. Nadler,et al.  Survival of pancreatic islet xenografts in NOD mice with the theracyte device. , 2002, Transplantation proceedings.